Pituitary tumors: Diagnosis, management, and implications for reproduction

Seminars in Reproductive Medicine

Volumn 25, Issue 5, 2007, Pages 388-401

  Beshay, Victor E ^a   Beshay, Joseph E ^a   Halvorson, Lisa M ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adenoma; Pituitary; Prolactinoma; Reproduction

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; FOLLITROPIN; GONADOTROPIN; KETOCONAZOLE; LUTEINIZING HORMONE; METHYLDOPA; MONOAMINE OXIDASE INHIBITOR; PROPYLTHIOURACIL; SEROTONIN UPTAKE INHIBITOR; THIAMAZOLE; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL;

ADENOMA; ANOREXIA; BLURRED VISION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOTROPIN BLOOD LEVEL; CUSHING DISEASE; DOSE RESPONSE; DROWSINESS; DRUG DOSE INCREASE; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; GENE THERAPY; GYNECOLOGY; HEADACHE; HEPATITIS; HIRSUTISM; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; HYPOPHYSIS APOPLEXY; HYPOPHYSIS CARCINOMA; HYPOPHYSIS DISEASE; HYPOPHYSIS TUMOR; IMMUNOCYTOCHEMISTRY; INFERTILITY; INJURY; INSOMNIA; LEG CRAMP; MENSTRUATION DISORDER; NAUSEA AND VOMITING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PROLACTINOMA; PSYCHOSIS; REPRODUCTION; REVIEW; SYNCOPE; THYROIDECTOMY; THYROTROPIN SECRETING ADENOMA;

ACTH-SECRETING PITUITARY ADENOMA; CARCINOMA; FEMALE; FERTILITY; FOLLICLE STIMULATING HORMONE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; LUTEINIZING HORMONE; MENSTRUAL CYCLE; PITUITARY NEOPLASMS; PROLACTINOMA; REPRODUCTION; THYROTROPIN;

EID: 34548363811     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984745     Document Type: Review

References (120)

1. Burrow GN, Wortzman G, Rewcastle NB, et al. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 1981;304(3):156-158
2. Molitch ME, Russell EJ. The pituitary "incidentaloma". Ann Intern Med 1990;112(12):925-931
3. Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994;120(10):817-820
4. Ezzat S, Asa SL. Mechanisms of disease: the pathogenesis of pituitary tumors. Nat Clin Pract Endocrinol Metab 2006;2(4):220-230
5. Kaltsas GA, Nomikos P, Kontogeorgos G, et al. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005;90(5):3089-3099
6. Pernicone PJ, Scheithauer BW, Sebo TJ, et al. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 1997;79(4):804-812
7. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101(3):613-619
8. Ruscalleda J. Imaging of parasellar lesions. Eur Radiol 2005;15(3):549-559
9. Bonneville JF, Bonneville F, Cattin F. Magnetic resonance imaging of pituitary adenomas. Eur Radiol 2005;15(3):543-548
10. Seilicovich A, Pisera D, Sciascia SA, et al. Gene therapy for pituitary tumors. Curr Gene Ther 2005;5(6):559-572
11. Modest GA, Fangman JJ. Nipple piercing and hyperprolactinemia. N Engl J Med 2002;347(20):1626-1627
12. Pollock A, McLaren EH. Serum prolactin concentration in patients taking neuroleptic drugs. Clin Endocrinol (Oxf) 1998;49(4):513-516
13. Slater SL, Lipper S, Shiling DJ, et al. Elevation of plasma-prolactin by monoamine-oxidase inhibitors. Lancet 1977;2(8032):275-276
14. Wiegand M, Berger M. Action of trimipramine on sleep and pituitary hormone secretion. Drugs 1989;38(suppl):135-142
15. Peterson MC. Reversible galactorrhea and prolactin elevation related to fluoxetine use. Mayo Clin Proc 2001;76(2):215-216
16. Steiner J, Cassar J, Mashiter K, et al. Effects of methyldopa on prolactin and growth hormone. BMJ 1976;1(6019):1186-1188
17. Fearrington EL, Rand CH Jr, Rose JD. Hyperprolactinemia-galactorrhea induced by verapamil. Am J Cardiol 1983;51(8):1466-1467
18. Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis 1985;6(4):245-249
19. Stryker TD, Molitch ME. Reversible hyperthyrotropinemia, hyperthyroxinemia, and hyperprolactinemia due to adrenal insufficiency. Am J Med 1985;79(2):271-276
20. Van Gaal L, Abs R, De Leeuw I, et al. Hypothyroidism and prolactin. Eur J Obstet Gynecol Reprod Biol 1981;12(5):315-321
21. Haisenleder DJ, Ortolano GA, Dalkin AC, et al. Differential actions of thyrotropin (TSH)-releasing hormone pulses in the expression of prolactin and TSH subunit messenger ribonucleic acid in rat pituitary cells in vitro. Endocrinology 1992;130(5):2917-2923
22. Fahie-Wilson MN, John R, Ellis AR. Macroprolactin: high molecular mass forms of circulating prolactin. Ann Clin Biochem 2005;42(pt 3):175-192
23. Davis JR. Prolactin and reproductive medicine. Curr Opin Obstet Gynecol 2004;16(4):331-337
24. McNeilly AS. Prolactin and the control of gonadotrophin secretion. J Endocrinol 1987;115(1):1-5
25. Glasow A, Breidert M, Haidan A, et al. Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland. J Clin Endocrinol Metab 1996;81(8):3103-3111
26. Vermeulen A, Ando S. Prolactin and adrenal androgen secretion. Clin Endocrinol (Oxf) 1978;8(4):295-303
27. Lobo RA, Kletzky OA. Normalization of androgen and sex hormone-binding globulin levels after treatment of hyperprolactinemia. J Clin Endocrinol Metab 1983;56(3):562-566
28. Frieze TW, Mong DP, Koops MK. "Hook effect" in prolactinomas: case report and review of literature. Endocr Pract 2002;8(4):296-303
29. St Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 1996;44(3):305-309
30. Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin North Am 2001;30(3):585-610
31. Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000;85(6):2247-2252
32. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994;331(14):904-909
33. Di Sarno A, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001;86(11):5256-5261
34. Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer 2001;8(4):287-305
35. Arafah BM, Brodkey JS, Pearson OH. Gradual recovery of lactotroph responsiveness to dynamic stimulation following surgical removal of prolactinomas: long-term follow-up studies. Metabolism 1986;35(10):905-912
36. Molitch ME, Thorner MO, Wilson C. Management of prolactinomas. J Clin Endocrinol Metab 1997;82(4):996-1000
37. Schlechte J, Dolan K, Sherman B, et al. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989;68(2):412-418
38. Jeffcoate WJ, Pound N, Sturrock ND, et al. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 1996;45(3):299-303
39. Klibanski A, Neer RM, Beitins IZ, et al. Decreased bone density in hyperprolactinemic women. N Engl J Med 1980;303(26):1511-1514
40. Biller BM, Baum HB, Rosenthal DI, et al. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992;75(3):692-697
41. Klibanski A, Biller BM, Rosenthal DI, et al. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988;67(1):124-130
42. Molitch ME. Management of prolactinomas during pregnancy. J Reprod Med 1999;44(12 suppl):1121-1126
43. Molitch ME. Pregnancy and the hyperprolactinemic woman. N Engl J Med 1985;312(21):1364-1370
44. Kupersmith MJ, Rosenberg C, Kleinberg D. Visual loss in pregnant women with pituitary adenomas. Ann Intern Med 1994;121(7):473-477
45. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 1996;14(4):228-238
46. Melmed S. Acromegaly. Metabolism 1996;45(8 suppl 1):51-52
47. Melmed S, Braunstein GD, Chang RJ, et al. Pituitary tumors secreting growth hormone and prolactin. Ann Intern Med 1986;105(2):238-253
48. Klibanski A, Zervas NT. Diagnosis and management of hormone-secreting pituitary adenomas. N Engl J Med 1991;324(12):822-831
49. Fukuda I, Hizuka N, Murakami Y, et al. Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women's Medical University. Intern Med 2001;40(10):987-992
50. Blumberg DL, Sklar CA, David R, et al. Acromegaly in an infant. Pediatrics 1989;83(6):998-1002
51. Chandrashekar V, Bartke A. The role of insulin-like growth factor-I in neuroendocrine function and the consequent effects on sexual maturation: inferences from animal models. Reprod Biol 2003;3(1):7-28
52. Lackey BR, Gray SL, Henricks DM. The insulin-like growth factor (IGF) system and gonadotropin regulation: actions and interactions. Cytokine Growth Factor Rev 1999;10(3-4):201-217
53. Barreca A, Artini PG, Del Monte P, et al. In vivo and in vitro effect of growth hormone on estradiol secretion by human granulosa cells. J Clin Endocrinol Metab 1993;77(1):61-67
54. Adashi EY, Resnick CE, D'Ercole AJ, et al. Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function. Endocr Rev 1985;6(3):400-420
55. Christman GM, Randolph JF Jr, Peegel H, et al. Differential responsiveness of luteinized human granulosa cells to gonadotropins and insulin-like growth factor I for induction of aromatase activity. Fertil Steril 1991;55(6):1099-1105
56. Erickson GF, Garzo VG, Magoffin DA. Insulin-like growth factor-I regulates aromatase activity in human granulosa and granulosa luteal cells. J Clin Endocrinol Metab 1989;69(4):716-724
57. Minegishi T, Hirakawa T, Abe K, et al. Effect of IGF-1 and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on the expression of LH receptors during cell differentiation in cultured granulosa cells. Mol Cell Endocrinol 2003;202(1-2):123-131
58. Kaltsas GA, Mukherjee JJ, Jenkins PJ, et al. Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab 1999;84(8):2731-2735
59. Luboshitzky R, Dickstein G, Barzilai D. Bromocriptine-induced pregnancy in an acromegalic patient. JAMA 1980;244(6):584-586
60. Lim NY, Dingman JF. Androgenic adrenal hyperfunction in acromegaly. N Engl J Med 1964;271:1189-1194
61. Unal A, Sahin Y, Kelestimur F. Acromegaly with polycystic ovaries, hyperandrogenism, hirsutism, insulin resistance and acanthosis nigricans: a case report. Endocr J 1993;40(2):207-211
62. Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 1988;67(1):69-73
63. Arafah BM, Rosenzweig JL, Fenstermaker R, et al. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly. J Lab Clin Med 1987;109(3):346-354
64. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000;85(2):526-529
65. Matsuno A, Ogino Y, Katayama H, et al. Identification of a silent pituitary somatotropic adenoma based on a paradoxic response of growth hormone on a thyrotropin-releasing hormone or gonadotropin-releasing hormone provocation test. Am J Obstet Gynecol 2001;184(3):286-288
66. Halse J, Harris AG, Kvistborg A, et al. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects. J Clin Endocrinol Metab 1990;70(5):1254-1261
67. Ayuk J, Stewart SE, Stewart PM, et al. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 2002;87(9):4142-4146
68. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86(6):2779-2786
69. Schoof E, Dorr HG, Kiess W, et al. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism-effect of octreotide therapy. Horm Res 2004;61(4):184-189
70. Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, et al. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab 1998;83(9):3083-3088
71. Cunningham SK, McKenna TJ. Dissociation of adrenal androgen and cortisol secretion in Cushing's syndrome. Clin Endocrinol (Oxf) 1994;41(6):795-800
72. Ahima RS, Harlan RE. Glucocorticoid receptors in LHRH neurons. Neuroendocrinology 1992;56(6):845-850
73. Chrousos GP, Schuermeyer TH, Doppman J, et al. NIH conference. Clinical applications of corticotropin-releasing factor. Ann Intern Med 1985;102(3):344-358
74. Fukata J, Nakai Y, Imura H, et al. Human corticotropin-releasing hormone test in normal subjects and patients with hypothalamic, pituitary or adrenocortical disorders. Endocrinol Jpn 1988;35(3):491-502
75. Kalgikar AM, Chandratreya SA, Goel A, et al. Inferior petrosal sinus sampling in the diagnostic evaluation of Cushing's syndrome: K.E.M. experience. J Assoc Physicians India 2005;53:685-688
76. Booth GL, Redelmeier DA, Grosman H, et al. Improved diagnostic accuracy of inferior petrosal sinus sampling over imaging for localizing pituitary pathology in patients with Cushing's disease. J Clin Endocrinol Metab 1998;83(7):2291-2295
77. Findling JW, Tyrrell JB. Occult ectopic secretion of corticotropin. Arch Intern Med 1986;146(5):929-933
78. Landolt AM, Valavanis A, Girard J, et al. Corticotrophin-releasing factor-test used with bilateral, simultaneous inferior petrosal sinus blood-sampling for the diagnosis of pituitary-dependent Cushing's disease. Clin Endocrinol (Oxf) 1986;25(6):687-696
79. Tindall GT, Herring CJ, Clark RV, et al. Cushing's disease: results of transsphenoidal microsurgery with emphasis on surgical failures. J Neurosurg 1990;72(3):363-369
80. Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med 1988;109(6):487-493
81. Semple PL, Vance ML, Findling JW, et al. Transsphenoidal surgery for Cushing's disease: outcome in patients with a normal magnetic resonance imaging scan. Neurosurgery 2000;46(3):553-558
82. Kurosaki M, Luedecke DK, Knappe UJ, et al. The value of intraoperative cytology during transsphenoidal surgery for ACTH-secreting microadenoma. Acta Neurochir (Wien) 2000;142(8):865-870
83. Esposito F, Dusick JR, Cohan P, et al. Clinical review: early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 2006;91(1):7-13
84. Nakane T, Kuwayama A, Watanabe M, et al. Long term results of transsphenoidal adenomectomy in patients with Cushing's disease. Neurosurgery 1987;21(2):218-222
85. Shimon I, Ram Z, Cohen ZR, et al. Transsphenoidal surgery for Cushing's disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 2002;51(1):57-61
86. Chaidarun SS, Klibanski A. Gonadotropinomas. Semin Reprod Med 2002;20(4):339-348
87. Samuels MH, Ridgway EC. Glycoprotein-secreting pituitary adenomas. Baillieres Clin Endocrinol Metab 1995;9(2):337-358
88. Klibanski A. Nonsecreting pituitary tumors. Endocrinol Metab Clin North Am 1987;16(3):793-804
89. Jameson JL, Klibanski A, Black PM, et al. Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas. J Clin Invest 1987;80(5):1472-1478
90. Yamada S, Asa SL, Kovacs K, et al. Analysis of hormone secretion by clinically nonfunctioning human pituitary adenomas using the reverse hemolytic plaque assay. J Clin Endocrinol Metab 1989;68(1):73-80
91. Hanson PL, Aylwin SJ, Monson JP, et al. FSH secretion predominates in vivo and in vitro in patients with non-functioning pituitary adenomas. Eur J Endocrinol 2005;152(3):363-370
92. Ghayuri M, Liu JH. Ovarian hyperstimulation syndrome caused by pituitary gonadotroph adenoma secreting follicle-stimulating hormone. Obstet Gynecol 2007;109(2 pt2):547-549
93. Shimon I, Rubinek T, Bar-Hava I, et al. Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 2001;86(8):3635-3640
94. Kihara M, Sugita T, Nagai Y, et al. Ovarian hyperstimulation caused by gonadotroph cell adenoma: a case report and review of the literature. Gynecol Endocrinol 2006;22(2):110-113
95. Tashiro H, Katabuchi H, Ohtake H, et al. A follicle-stimulating hormone-secreting gonadotroph adenoma with ovarian enlargement in a 10-year-old girl. Fertil Steril 1999;72(1):158-160
96. Roberts JE, Spandorfer S, Fasouliotis SJ, et al. Spontaneous ovarian hyperstimulation caused by a follicle-stimulating hormone-secreting pituitary adenoma. Fertil Steril 2005;83(1):208-210
97. Ambrosi B, Bassetti M, Ferrario R, et al. Precocious puberty in a boy with a PRL-, LH- and FSH-secreting pituitary tumour: hormonal and immunocytochemical studies. Acta Endocrinol (Copenh) 1990;122(5):569-576
98. Faggiano M, Criscuolo T, Perrone L, et al. Sexual precocity in a boy due to hypersecretion of LH and prolactin by a pituitary adenoma. Acta Endocrinol (Copenh) 1983;102(2):167-172
99. Cook DM, Watkins S, Snyder PJ. Gonadotrophin-secreting pituitary adenomas masquerading as primary ovarian failure. Clin Endocrinol (Oxf) 1986;25(6):729-738
100. Somjen D, Tordjman K, Kohen F, et al. Combined beta FSH and beta LH response to TRH in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol (Oxf) 1997;46(5):555-562
101. Lamberts SW, Verleun T, Oosterom R, et al. The effects of bromocriptine, thyrotropin-releasing hormone, and gonadotropin-releasing hormone on hormone secretion by gonadotropin-secreting pituitary adenomas in vivo and in vitro. J Clin Endocrinol Metab 1987;64(3):524-530
102. White MC, Daniels M, Newland P, et al. LH and FSH secretion and responses to GnRH and TRH in patients with clinically functionless pituitary adenomas. Clin Endocrinol (Oxf) 1990;32(6):681-688
103. Chanson P, Schaison G. Pituitary apoplexy caused by GnRH-agonist treatment revealing gonadotroph adenoma. J Clin Endocrinol Metab 1995;80(7):2267-2268
104. Frankart L, De Hertogh R, Donckier J, et al. Pituitary apoplexy of a gonadotrophinoma and TRH/GnRH tests. Literature review. Acta Clin Belg 1995;50(3):163-170
105. Shomali ME, Katznelson L. Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas. Pituitary 2002;5(2):89-98
106. Sassolas G, Lejeune H, Trouillas J, et al. Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1988;67(1):180-185
107. McGrath GA, Goncalves RJ, Udupa JK, et al. New technique for quantitation of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 1993;76(5):1363-1368
108. Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996;17(6):610-638
109. Southren AL, Olivo J, Gordon GG, et al. The conversion of androgens to estrogens in hyperthyroidism. J Clin Endocrinol Metab 1974;38(2):207-214
110. Akande EO, Hockaday TD. Plasma concentration of gonadotrophins, oestrogens and progesterone in thyrotoxic women. Br J Obstet Gynaecol 1975;82(7):541-551
111. Kalro BN. Impaired fertility caused by endocrine dysfunction in women. Endocrinol Metab Clin North Am 2003;32(3):573-592
112. Beck-Peccoz P, Persani L. Medical management of thyrotropin-secreting pituitary adenomas. Pituitary 2002;5(2):83-88
113. Kourides IA, Ridgway EC, Weintraub BD, et al. Thyrotropin-induced hyperthyroidism: use of alpha and beta subunit levels to identify patients with pituitary tumors. J Clin Endocrinol Metab 1977;45(3):534-543
114. Beck-Peccoz P, Persani L, Faglia G. Glycoprotein hormone alpha-subunit in pituitary-adenomas. Trends Endocrinol Metab 1992;3(2):41-45
115. Bertherat J, Brue T, Enjalbert A, et al. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions. J Clin Endocrinol Metab 1992;75(2):540-546
116. Kuhn JM, Arlot S, Lefebvre H, et al. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 2000;85(4):1487- 1491
117. Caron P, Arlot S, Bauters C, et al. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 2001;86(6):2849-2853
118. Fischler MP, Reinhart WH. TSH-secreting pituitary macroadenoma: rapid tumor shrinkage and recovery from hyperthyroidism with octreotide. J Endocrinol Invest 1999;22(1):64-65
119. Faglia G, Beck-Peccoz P, Piscitelli G, et al. Inappropriate secretion of thyrotropin by the pituitary. Horm Res 1987;26(1-4):79-99
120. Wollesen F, Andersen T, Karle A. Size reduction of extrasellar pituitary tumors during bromocriptine treatment. Ann Intern Med 1982;96(3):281-286